Screener
Viridian Therapeutics, Inc. VRDN Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Weighted-average Series B convertible preferred shares outstanding, basic and diluted | 70,270 | 145,160 | 74,920 | 145,160 |
| Comprehensive loss: | ||||
| Net loss | $(127,119) | $(100,735) | $(232,020) | $(187,647) |
| Other comprehensive income (loss): | ||||
| Unrealized gain (loss) on available-for-sale securities | (598) | (176) | (1,606) | 79 |
| Foreign currency translation adjustment | 3 | — | 6 | — |
| Total other comprehensive income (loss) | (595) | (176) | (1,600) | 79 |
| Comprehensive loss | $(127,714) | $(100,911) | $(233,620) | $(187,568) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Viridian Therapeutics, Inc. (VRDN) reported comprehensive income (loss), net of tax, attributable to parent of -$127.71M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Viridian Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 26.6% year-over-year, from -$100.91M to -$127.71M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 44.0% compound annual growth rate (CAGR), from -$79.56M to -$342.14M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on securities. It provides a comprehensive view of the company's financial performance by including all recognized revenues, expenses, gains, and losses. Investors use this to assess the total impact of all financial activities on the company's net worth beyond standard operating results.
Ask your AI about Viridian Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude